DHODH and neoplasm: DHODH inhibitors have demonstrated anticancer activity in different preclinical tumor models (223–225), including AML (226), and are currently tested in a phase I trial for patients with acute myeloid leukemia and myelodysplastic syndrome (NCT04609826).